Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study

Por Lee, Jong Wook, Yoon, Sung-Soo, Shen, Zhi Xiang, Ganser, Arnold, Hsu, Hui-Chi, El-Ali, Ali, Habr, Dany, Martin, Nicolas, Porter, John B.
Publicado em 2013

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

Por Taher, Ali, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, El-Ali, Ali, Roubert, Bernard, El-Beshlawy, Amal
Publicado em 2011